What is the appropriate treatment for an outbreak of shingles?

Treatment for Shingles (Herpes Zoster)

For uncomplicated shingles, initiate oral valacyclovir 1 gram three times daily or famciclovir 500 mg three times daily within 72 hours of rash onset, continuing for 7-10 days until all lesions have completely scabbed. 1

First-Line Oral Antiviral Therapy

Valacyclovir and famciclovir are preferred over acyclovir due to superior bioavailability and less frequent dosing, which improves adherence and potentially reduces pain more effectively. 1

Standard Dosing Regimens

• Valacyclovir 1000 mg orally three times daily for 7 days is the preferred first-line option 1
• Famciclovir 500 mg orally three times daily for 7 days offers equivalent efficacy with convenient dosing 1, 2
• Acyclovir 800 mg orally five times daily for 7-10 days remains effective but requires more frequent administration 1, 3

Critical Timing Window

Treatment must be initiated within 72 hours of rash onset to achieve optimal efficacy in reducing acute pain, accelerating lesion healing, and preventing postherpetic neuralgia. 1 Starting treatment during the prodrome or within 48 hours provides maximum benefit, though the 72-hour window is the accepted cutoff. 1

Treatment Duration Endpoint

Continue antiviral therapy until all lesions have completely scabbed, not just for an arbitrary 7-day period. 1 If lesions are still forming or have not scabbed at day 7, extend treatment duration—short-course regimens designed for genital herpes (1-3 days) are inadequate for varicella-zoster virus infection. 1

Indications for Intravenous Acyclovir

Switch to intravenous acyclovir 10 mg/kg every 8 hours when any of the following are present: 1

• Disseminated herpes zoster (≥3 dermatomes, visceral involvement, or hemorrhagic lesions)
• Severe immunosuppression (active chemotherapy, HIV with low CD4 count, organ transplant recipients)
• Central nervous system complications (encephalitis, meningitis, Guillain-Barré syndrome)
• Complicated facial or ophthalmic disease with risk of cranial nerve involvement
• Lack of clinical improvement after 7-10 days of oral therapy, suggesting possible acyclovir resistance 1

Continue IV therapy for a minimum of 7-10 days and until all lesions have completely scabbed. 1

Special Populations

Immunocompromised Patients

For severely immunocompromised patients (chemotherapy, HIV, organ transplant), initiate intravenous acyclovir 10 mg/kg every 8 hours immediately due to high risk of dissemination and vision-threatening complications. 1 Consider temporary reduction or discontinuation of immunosuppressive medications in cases of disseminated or invasive herpes zoster if clinically feasible. 1

Renal Impairment

Assess baseline renal function before starting antivirals and adjust dosing based on creatinine clearance. 1 For valacyclovir: 1

• CrCl 30-49 mL/min: 500 mg-1 g every 12 hours
• CrCl 10-29 mL/min: 500 mg-1 g every 24 hours
• CrCl <10 mL/min: 500 mg every 24 hours

Monitor renal function weekly during IV acyclovir therapy to detect nephrotoxicity early. 1 Ensure adequate hydration to reduce the risk of crystalluria and obstructive nephropathy, which occurs in up to 20% of patients. 1

Facial or Ophthalmic Involvement

Facial zoster requires particular urgency due to risk of ophthalmic complications and cranial nerve involvement. 1 Initiate oral valacyclovir 1 gram three times daily or famciclovir 500 mg three times daily within 72 hours, continuing until all lesions have scabbed. 1 Ocular involvement generally merits referral to an ophthalmologist. 3

Management of Acyclovir-Resistant Herpes Zoster

Suspect acyclovir resistance if lesions fail to improve within 7-10 days of appropriate therapy. 1 Confirm with viral culture and susceptibility testing. 1

For proven or suspected acyclovir-resistant VZV, switch to foscarnet 40 mg/kg IV every 8 hours until clinical resolution. 1 All acyclovir-resistant strains are also resistant to valacyclovir, and most are resistant to famciclovir. 1 Topical cidofovir gel 1% applied once daily for 5 consecutive days may be an alternative for external lesions. 1

Confirmed resistance is extremely rare in immunocompetent patients but occurs in up to 7% of immunocompromised patients, particularly those on prolonged suppressive therapy. 1

Adjunctive Pain Management

Acute Neuropathic Pain

Gabapentin is the first-line oral agent for acute neuropathic pain due to herpes zoster, titrated in divided doses up to 2400 mg per day. 1 Somnolence occurs in approximately 80% of treated individuals, so counsel patients accordingly. 1

Pregabalin may be added for patients whose pain remains uncontrolled with gabapentin alone. 1 Over-the-counter analgesics such as acetaminophen and ibuprofen can relieve acute pain in otherwise healthy adults. 1

Topical Therapies

A single application of an 8% capsaicin patch provides analgesia lasting at least 12 weeks for chronic peripheral neuropathic pain. 1 To mitigate erythema and burning, apply 4% lidocaine for 60 minutes before capsaicin administration. 1

Topical antiviral agents should be avoided because they are substantially less effective than systemic therapy and do not improve outcomes. 1, 3

Corticosteroid Considerations

Prednisone may be used as adjunctive therapy to antivirals in select cases of severe, widespread shingles in immunocompetent patients. 1 However, prednisone should generally be avoided in immunocompromised patients due to increased risk of disseminated infection. 1 The risks—including infections, hypertension, myopathy, glaucoma, osteopenia, and Cushing syndrome—often outweigh modest pain reduction benefits, particularly in elderly patients. 1

Infection Control Measures

Patients with herpes zoster should avoid contact with susceptible individuals until all lesions have crusted, as lesions are contagious to individuals who have not had chickenpox or vaccination. 1 Cover lesions with clothing or dressings to minimize transmission risk. 1

For disseminated zoster (lesions in >3 dermatomes), implement both airborne and contact precautions in healthcare settings. 1 Physical separation of at least 6 feet from other patients is recommended. 1

Prevention of Future Episodes

The recombinant zoster vaccine (Shingrix) is strongly recommended for all adults aged ≥50 years, regardless of prior herpes zoster episodes, providing >90% efficacy in preventing future recurrences. 1 Vaccination should ideally occur before initiating immunosuppressive therapies but can also be given after recovery from an acute episode. 1

For patients on B-cell depleting therapies (ocrelizumab, rituximab, ofatumumab), administer Shingrix at least 4 weeks prior to the next scheduled dose to maximize immunogenicity. 1

Common Pitfalls to Avoid

• Do not discontinue antiviral therapy at exactly 7 days if lesions are still forming or have not completely scabbed—treatment duration is guided by lesion healing, not calendar days. 1
• Do not use topical acyclovir for shingles—it is substantially less effective than systemic therapy. 1
• Do not delay treatment beyond 72 hours of rash onset—efficacy diminishes significantly after this window. 1
• Do not use oral antivirals in severely immunocompromised patients with disseminated disease—IV acyclovir is mandatory. 1
• Do not forget to adjust antiviral dosing for renal impairment—failure to do so can cause acute renal failure. 1